Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/instruments, including automated nucleic acid extraction, automatic medical PCR analysis, flow-through hybridization, auto DNA extraction, and fluorescent quantitative detection systems, as well as after-sales technical service support. Its products are used in the fields of national screening, clinical, and research purposes. The company operates in the Asia Pacific, the South East Asia, the Middle East, Europe, Africa, and South America. The company was founded in 2003 and is based in Chaozhou, China.
Frequently asked questions
What sector does Guangdong Hybribio Biotech Co Ltd (300639) operate in?
Guangdong Hybribio Biotech Co Ltd belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is Guangdong Hybribio Biotech Co Ltd (300639) current stock price?
As of the latest data, Guangdong Hybribio Biotech Co Ltd stock price is CN¥6.22, with a previous close of CN¥6.22.
What is Guangdong Hybribio Biotech Co Ltd (300639) current market capitalization?
Guangdong Hybribio Biotech Co Ltd market cap is approximately 4.02 billion.
What is Guangdong Hybribio Biotech Co Ltd (300639) Earnings Per Share (EPS)?
The trailing EPS is -CN¥0.02.
Does Guangdong Hybribio Biotech Co Ltd (300639) pay dividends?
No. Guangdong Hybribio Biotech Co Ltd does not pay a dividend.
What is Guangdong Hybribio Biotech Co Ltd (300639) beta (volatility) score?
Guangdong Hybribio Biotech Co Ltd has a beta of 0.416, indicating lower volatility than the overall market.
